Patents by Inventor STEPHANIE CHANTEUX

STEPHANIE CHANTEUX has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF CANCER
    Publication number: 20240325557
    Abstract: The invention relates to antigen-binding proteins capable of binding to Nectin-4 polypeptides conjugated to chemotherapeutic agents, for use in increasing sensitivity of tumors to the chemotherapeutic agents and for use in the treatment of cancers characterized by Nectin-4-expressing tumor cells.
    Type: Application
    Filed: November 24, 2021
    Publication date: October 3, 2024
    Inventors: MANEL KRAIEM, STÉPHANIE CHANTEUX, BENJAMIN ROSSI
  • TREATMENT OF CANCER WITH ILT-2 INHIBITORS
    Publication number: 20240294634
    Abstract: This invention relates to the use of a NKG2A-neutralizing agent and an antibody that inhibits human ILT2 to treat cancer, particularly a head and neck squamous cell carcinoma (HNSCC), a lung cancer, optionally an NSCLC, a renal cell carcinoma, a colorectal carcinoma, a urothelial cancer or an ovarian cancer.
    Type: Application
    Filed: October 13, 2020
    Publication date: September 5, 2024
    Inventors: OLIVIER BENAC, STÉPHANIE CHANTEUX, IVAN PERROT, BENJAMIN ROSSI, NICOLAS VIAUD
  • IMMUNOHISTOCHEMISTRY METHODS AND KIR3DL2-SPECIFIC REAGENTS
    Publication number: 20240117042
    Abstract: The present invention relates to antibodies and methods for detecting KIR3DL2 expression in paraffin-embedded tissue samples. Also provide are methods of making antibodies, antibody fragments, and derivatives thereof that specifically bind to their target antigen in paraffin-embedded tissue samples.
    Type: Application
    Filed: April 4, 2022
    Publication date: April 11, 2024
    Inventors: BENJAMIN ROSSI, STÉPHANIE CHANTEUX, ROMAIN REMARK, CÉCILE BONNAFOUS, CLARENCE DEFFAUD, THIBAUT PELAT
  • COMPOUNDS AND METHODS FOR TREATMENT OF HEAD AND NECK CANCER
    Publication number: 20220025045
    Abstract: This invention relates to the use of ILT-2-targeting agents for the treatment of cancers head and neck cancers. This invention also provides advantageous combination regimens for use with ILT-2-targeting agents for the treatment of cancers.
    Type: Application
    Filed: December 20, 2019
    Publication date: January 27, 2022
    Inventors: OLIVIER BENAC, STÉPHANIE CHANTEUX, IVAN PERROT, BENJAMIN ROSSI, NICOLAS VIAUD
  • LEUCOCYTE IMMUNOGLOBULIN-LIKE RECEPTOR NEUTRALIZING ANTIBODIES
    Publication number: 20220025056
    Abstract: This invention relates to agents that bind and neutralize the inhibitory activity of human ILT2 proteins having inhibitory activity in NK cells, T cells and/or other immune cells. Such agents can be used for the treatment of cancers or infectious disease.
    Type: Application
    Filed: December 20, 2019
    Publication date: January 27, 2022
    Inventors: OLIVIER BENAC, STÉPHANIE CHANTEUX, IVAN PERROT, BENJAMIN ROSSI, NICOLAS VIAUD
  • CD73 BLOCKADE
    Publication number: 20180030144
    Abstract: This invention relates to antibodies that bind an epitope present on CD73 expressed at the surface of cells, including tumor cells, and that inhibit the enzymatic (ecto-5? nucleotidase) activity of the CD73 enzyme. Such agents can be used for the treatment of diseases such as cancers.
    Type: Application
    Filed: February 19, 2016
    Publication date: February 1, 2018
    Inventors: STEPHANIE CHANTEUX, CARINE PATUREL, IVAN PERROT, LAURENT GAUTHIER